|UCB SA -- USA Stock|| |
USD 37.31 0.33 0.88%
Non-Executive Vice Chairwoman of the Board
Mrs. Evelyn Diego du Monceau de Bergendal was appointed NonExecutive Chairman of the Board of UCB S.A. with effect from April 27, 2017. Prior to that, she has served as NonExecutive Vice Chairwoman of the Board of the Company since June 13, 2006. Between 1984 and June 13, 2006, she served as NonExecutive Director of the Company. She also is Chair of the Governance, Nomination and Compensation Committee since 2006. She graduated in Applied Economics from Universite catholique de Louvain in Belgium in 1972. She followed courses in International Relations at the Kennedy School of Harvard University and in Soil Science, Animal Science and Zoology at the Agricultural and Technical College of Farmingdale . She was Member of the Board of Directors of Financiere de Tubize and member of the Board of Solvay S.A. She has acted as Member of the Nomination and of the Remuneration Committees of Solvay S.A.
Age: 66 Executive Since 2017
32 2 559 99 99 http://www.ucb-group.com
The company has return on total asset (ROA)
of 5.76 %
which means that it generated profit of $5.76 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 13.02 %
meaning that it generated $13.02 on every $100 dollars invested by stockholders.
The company has accumulated 1.85 B in total debt with debt to equity ratio (D/E) of 28.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. UCB SA has Current Ratio of 1.09 suggesting that it may not have the ability to pay its financial obligations in time and when they become due.
UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB SA (UCBJY) is traded on OTC Market in USA. It is located in Allée de la Recherche, Brussels, and employs 7,643 people.